Alzheimer's Drug Poses a Dilemma for the F.D.A.
2 min read
If the agency approves it, aducanumab would be the first new Alzheimer's treatment since 2003. Patients are desperate for new options, but some scientists say there isn't enough evidence it works.
The Food and Drug Administration is on the verge of announcing one of its most contentious decisions in years: the fate of an Alzheimer's drug that could be the first treatment approved after nearly two decades of failed efforts to find ways to curb the debilitating disease.

On Monday, the agency will rule on the drug, aducanumab,…
Pam Belluck, Rebecca Robbins
Read full article